GPNMB-ECD drives acquired resistance to osimertinib in NSCLC via inducing tumor cell cytoskeletal reorganization
{{output}}
Background: Acquired resistance constitutes a major obstacle to the efficacy of osimertinib therapy in nonsmall-cell lung cancer (NSCLC), yet its underlying mechanisms remain incompletely understood. While the soluble extracellul... ...
